Hutschalik, Thomas
Özgül, Ozan
Casini, Marilù
Szabó, Brigitta
Peyronnet, Rémi
Bártulos, Óscar
Argenziano, Mariana
Schotten, Ulrich
Matsa, Elena
Funding for this research was provided by:
H2020 Marie Skłodowska-Curie Actions (860974)
Article History
Received: 2 January 2024
Accepted: 24 June 2024
First Online: 4 September 2024
Declarations
:
: This study did not involve the handling of any animals or human primary material. iPSC lines were derived following informed consent and appropriate ethical approval by the source institutions (LUMC; Commissie Medische Ethiek LUMC: P13.080 and NIH; Institutional Biosafety Committee at Sanford Research: 2015101) for the generation, use, and distribution of the cell lines used in this study. Lines were obtained from these institutions under a material transfer agreement (MTA) and were used under guidelines outlined in the ethical approvals. This study also used publicly available metadata from the CATCH ME trial []. Informed consent and ethical approval for the CATCH ME consortium was obtained from the Medical Ethics Committee of each participating center, as described in the original study [].
: Not applicable.
: TH, BS, OB, MA, EM: Ncardia Services B.V. is a privately held Biotech company offering drug discovery, drug safety and cardiac disease modelling services commercially.